Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 2, 2026

SK Telecom CEO Unveils 'AI Native' Strategy at MWC26, Driving Korea's Leap in AI Innovation

View original at finance.yahoo.com
SK Telecom CEO Unveils 'AI Native' Strategy at MWC26, Driving Korea's Leap in AI Innovation - Seizing the golden time for a major transformation, with 'Customer Value & AI' as the top two priorities for driving change - Major overhaul of systems and infrastructure, the foundation of telecommunications, centered on AI -…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • To drive future growth, we must reinvent our way of working from the ground up. SKT will fundamentally transform its corporate culture to be centered around AI

    80% confidence

  • SKT is currently at a golden time of transformation, where the two tasks of customer value innovation and AI innovation intersect in a borderless, converged environment that goes beyond telecommunications

    80% confidence

  • AIDC can be seen as the heart of Korea, and hyperscale LLMs as the brain. By combining SKT's AI capabilities with collaboration from domestic and global partners, we will lead true AI-native transformation for Korean customers and enterprises

    80% confidence

  • By implementing company-wide AI upskilling education and campaigns, we will transform our organizational culture to be AI Native. Through SKT's new transformation, we will do our utmost to regain the trust of our customers and become a company that contributes to the nation and society

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com